TERT Promoter Methylation is Significantly Associated with TERT Upregulation and Disease Progression in Pituitary Adenomas

Overview

Journal J Neurooncol

Publisher Springer

Date 2018 Nov 5

PMID 30392088

Citations 15

Authors

Yohei Miyake

Jun-Ichi Adachi

Tomonari Suzuki

Kazuhiko Mishima

Ryuichiro Araki

Reina Mizuno

Ryo Nishikawa

Affiliations

Soon will be listed here.

Abstract

Purpose: Alterations in the promoter of the telomerase reverse transcriptase (TERT) gene are a major mechanism of upregulating telomerase, which plays a crucial role in tumor development. Mutations in the TERT promoter have been observed in a subset of brain tumors, including adult gliomas and high-grade meningiomas. In pituitary adenomas (PAs), however, abnormalities in TERT are not fully understood. The present study aimed to investigate not only mutational but also methylation changes in the TERT promoter in PAs and to analyze their correlations with clinical variables.

Methods: We retrospectively studied 70 PAs consisting of 53 primary and 17 recurrent samples. Clinical data, including age at surgery, sex, largest tumor dimension, tumor subtype, resection rate, and progression-free survival (PFS), were obtained from medical records. We investigated TERT promoter hotspot mutations via Sanger sequencing and quantified the methylation status of the TERT promoter using methylation-sensitive high-resolution melting analysis (MS-HRM). Additionally, we investigated TERT mRNA expression using real-time quantitative PCR.

Results: TERT promoter hotspot mutations were not observed in any PA sample, while 16% of PAs exhibited TERT promoter methylation. PAs with methylated TERT promoters were significantly more likely to show disease progression, shorter PFS, and higher TERT expression levels compared to those with unmethylated promoters.

Conclusions: This is the first study showing that TERT promoter methylation is associated with disease progression and shorter PFS as well as upregulated TERT expression in PAs. Our results suggest that TERT promoter methylation may be a potential biomarker for predicting tumor recurrence in PAs.

Citing Articles

DNA Methylation in Pituitary Adenomas: A Scoping Review.

Moller M, Nortvig M, Andersen M, Poulsen F Int J Mol Sci. 2025; 26(2).

PMID: 39859246 PMC: 11765255. DOI: 10.3390/ijms26020531.

A review of current developments in RNA modifications in lung cancer.

Zhang S, Liu Y, Liu K, Hu X, Gu X Cancer Cell Int. 2024; 24(1):347.

PMID: 39456034 PMC: 11515118. DOI: 10.1186/s12935-024-03528-6.

High-Grade Progression, Sarcomatous Transformation, and/or Metastasis of Pituitary Neuroendocrine Neoplasms (PitNENs): The UCSF Experience.

Terry M, Nguyen M, Tang V, Guney E, Bharani K, Dahiya S Endocr Pathol. 2024; 35(4):338-348.

PMID: 39388031 PMC: 11659330. DOI: 10.1007/s12022-024-09829-w.

Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer.

Sang Y, Hu G, Xue J, Chen M, Hong S, Liu R Endocrine. 2024; 85(1):304-312.

PMID: 38356100 DOI: 10.1007/s12020-024-03722-6.

Gene Modification Using CRISPR-dCas9-dnmt3a System as a Therapeutic Approach Against Glioma.

Taghavi Rad F, Ghorbian S, Naghavi Gargari B, Shirvani Farsani Z, Sharifi R Iran J Pharm Res. 2023; 22(1):e137226.

PMID: 38116572 PMC: 10728856. DOI: 10.5812/ijpr-137226.

References

Dome J, Chung S, BERGEMANN T, Umbricht C, Saji M, Carey L . High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor. Cancer Res. 1999; 59(17):4301-7. View

Guilleret I, Yan P, Grange F, Braunschweig R, Bosman F, Benhattar J . Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer. 2002; 101(4):335-41. DOI: 10.1002/ijc.10593. View

Yoshino A, Katayama Y, Fukushima T, Watanabe T, Komine C, Yokoyama T . Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence. J Neurooncol. 2003; 63(2):155-62. DOI: 10.1023/a:1023935621976. View

Boldrini L, Pistolesi S, Gisfredi S, Ursino S, Ali G, Pieracci N . Telomerase activity and hTERT mRNA expression in glial tumors. Int J Oncol. 2006; 28(6):1555-60. DOI: 10.3892/ijo.28.6.1555. View

Wojdacz T, Dobrovic A . Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007; 35(6):e41. PMC: 1874596. DOI: 10.1093/nar/gkm013. View

Ortiz-Plata A, Tena Suck M, Lopez-Gomez M, Heras A, Sanchez Garcia A . Study of the telomerase hTERT fraction, PCNA and CD34 expression on pituitary adenomas. Association with clinical and demographic characteristics. J Neurooncol. 2007; 84(2):159-66. DOI: 10.1007/s11060-007-9365-8. View

Adachi J, Mishima K, Wakiya K, Suzuki T, Fukuoka K, Yanagisawa T . O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment. J Neurooncol. 2011; 107(1):147-53. DOI: 10.1007/s11060-011-0721-3. View

Hightower E, Cabanillas M, Fuller G, McCutcheon I, Hess K, Shah K . Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas. Pituitary. 2011; 15(4):556-61. PMC: 3852837. DOI: 10.1007/s11102-011-0367-3. View

Horn S, Figl A, Rachakonda P, Fischer C, Sucker A, Gast A . TERT promoter mutations in familial and sporadic melanoma. Science. 2013; 339(6122):959-61. DOI: 10.1126/science.1230062. View

10.

Huang F, Hodis E, Xu M, Kryukov G, Chin L, Garraway L . Highly recurrent TERT promoter mutations in human melanoma. Science. 2013; 339(6122):957-9. PMC: 4423787. DOI: 10.1126/science.1229259. View

11.

Bougel S, Lhermitte B, Gallagher G, de Flaugergues J, Janzer R, Benhattar J . Methylation of the hTERT promoter: a novel cancer biomarker for leptomeningeal metastasis detection in cerebrospinal fluids. Clin Cancer Res. 2013; 19(8):2216-23. DOI: 10.1158/1078-0432.CCR-12-1246. View

12.

Castelo-Branco P, Choufani S, Mack S, Gallagher D, Zhang C, Lipman T . Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol. 2013; 14(6):534-42. DOI: 10.1016/S1470-2045(13)70110-4. View

13.

Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A . Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 2013; 126(2):267-76. DOI: 10.1007/s00401-013-1141-6. View

14.

Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones D . Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013; 126(6):907-15. DOI: 10.1007/s00401-013-1195-5. View

15.

Arita H, Narita Y, Takami H, Fukushima S, Matsushita Y, Yoshida A . TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas. Acta Neuropathol. 2013; 126(6):939-41. DOI: 10.1007/s00401-013-1203-9. View

16.

Goutagny S, Nault J, Mallet M, Henin D, Rossi J, Kalamarides M . High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol. 2013; 24(2):184-9. PMC: 8029399. DOI: 10.1111/bpa.12110. View

17.

Lindsey J, Schwalbe E, Potluri S, Bailey S, Williamson D, Clifford S . TERT promoter mutation and aberrant hypermethylation are associated with elevated expression in medulloblastoma and characterise the majority of non-infant SHH subgroup tumours. Acta Neuropathol. 2013; 127(2):307-9. PMC: 4313075. DOI: 10.1007/s00401-013-1225-3. View

18.

Ieva A, Rotondo F, Syro L, Cusimano M, Kovacs K . Aggressive pituitary adenomas--diagnosis and emerging treatments. Nat Rev Endocrinol. 2014; 10(7):423-35. DOI: 10.1038/nrendo.2014.64. View

19.

Chatzellis E, Alexandraki K, Androulakis I, Kaltsas G . Aggressive pituitary tumors. Neuroendocrinology. 2015; 101(2):87-104. DOI: 10.1159/000371806. View

20.

Huang D, Wang Z, He X, Diplas B, Yang R, Killela P . Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer. 2015; 51(8):969-76. PMC: 4467782. DOI: 10.1016/j.ejca.2015.03.010. View